Also found in: Medical.
AASLDAmerican Association for the Study of Liver Diseases (Alexandria, VA)
References in periodicals archive ?
A total of six abstracts were accepted for presentation at AASLD, including presentations that contain off-study, follow-on data from a 14-day Phase 1b trial of telaprevir with pegylated interferon, and a 28-day Phase 1b trial of telaprevir with pegylated interferon and ribavirin.
Tibotec to present final safety and efficacy results from phase 2b PILLAR study of Once-daily TMC435 in late-breaker at AASLD
Additionally, there will be three poster presentations at the 2011 AASLD meeting.
Head of Liver Unit at the Erasmus MC University Hospital Rotterdam, The Netherlands and Lead Clinical Investigator of the study, who is presenting the data at AASLD.
Commenting on the announcement by Medivir's development partner, Tibotec, Ron Long, Chief Executive of Medivir, said: "We are very pleased to have such exciting TMC435 data presented by our partner, Tibotec, at the AASLD.
In the regularly revised HCV Practice Guidance of AASLD and Infectious Diseases Society of America we recommend early treatment of chronic HCV infection before the development of severe liver disease and other complications to improve overall survival rates.
Chief Medical Officer, will present a late-breaker poster, "Safety and Pharmacokinetics of PPI-461, a Potent New Hepatitis C virus (HCV) NS5A Inhibitor with Pan-Genotype Activity" at the 61st AASLD meeting in Boston, MA, on November 1, 2010.
Interim data from Tibotec's exploratory phase II study, VX950-C208, of telaprevir in treatment-naE[macron]ve patients with HCV genotype 1 were presented recently at AASLD.